A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

Exclusion Criteria

• •1. Prior treatment of the keloid scar in the previous 6 weeks.
• •2. The keloid scar must not have undergone prior surgical excisions (laser, cryotherapy or surgery).
• •3. The keloid scar must not have undergone prior radiation treatment.
• •4. Pregnant, lactating, or planning to become pregnant during the course of the study.
• •5. Advanced or poorly controlled diabetes.
• •6. Active local infection at the treatment site and/or systemic infection that would in the opinion of the Investigator affect the treatment site.
• •7. Any medical or surgical condition that will interfere with required study activities or assessments or that make the study treatments contraindicated in the opinion of the study Investigator.
• •8. Unwilling to refrain from use of any other scar treatment therapy/scar improving product, during the study.
• •9. Regular, continuous use of systemic corticosteroid therapy or topical corticosteroid use in the area to be treated.
• •10. Current participation or participation within the last 1 months in the study of an investigational drug, device, or biologic.
• •11. Unable or unwilling to follow post-operative instructions.
• •12. Mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study.
• •13. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds, or drug product excipients.